Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621302 | 0.90 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL1058888 | 0.88 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL8029227 | 0.85 | SIGMAR1 (0.64) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL129763 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL2079859 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL4205099 | 0.84 | SIGMAR1 (0.63) | SIGMAR1ALDH1A1CCR5HPGDL3MBTL1 | |
| SCHEMBL30865762 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL2621297 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL19139368 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD | |
| SCHEMBL25568168 | 0.84 | SIGMAR1 (0.53) | SIGMAR1ALDH1A1CCR5MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11834662-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11827883-B2 | Dosages and methods for delivering lipid formulated nucleic acid molecules | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365965-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | GENZYME CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332147-A1 | IRNA COMPOSITIONS AND METHODS FOR SILENCING GROWTH FACTOR RECEPTOR BOUND PROTEIN 10 (GRB10) OR GROWTH FACTOR RECEPTOR BOUND PROTEIN 14 (GRB14) IN THE LIVER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2011153323-A9 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011153323-A2 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20110251259-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011091396-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MYLIP/IDOL GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011071860-A2 | COMPOSITIONS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2011-01-20 | — | — | US | disclosed |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | ALNYLAM PHARMACEUTICALS, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010054406-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251259-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | CD274, PDCD1LG2, PDCD4 | SIGMAR1 4513/4885ALDH1A1 2685/4885CCR5 366/4885 |
| US-20230323357-A1 | TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | TRAF6, TRAF2, TNFRSF1A | SIGMAR1 4555/4885ALDH1A1 4243/4885CCR5 1393/4885 |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | SIGMAR1 3783/4885ALDH1A1 4655/4885CCR5 4396/4885 |
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | C5, RNASEH1, RNASEL | SIGMAR1 4810/4885ALDH1A1 2980/4885CCR5 872/4885 |
| US-11834662-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | SIGMAR1 4845/4885ALDH1A1 3659/4885CCR5 2677/4885 |
| US-20230365965-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SERPINC1, SERPINH1, SERPINE1 | SIGMAR1 4790/4885ALDH1A1 2236/4885CCR5 3065/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | SIGMAR1 4121/4885ALDH1A1 4792/4885CCR5 3949/4885 |
| US-11840692-B2 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | TEK, RNASE1, LDLR | SIGMAR1 4845/4885ALDH1A1 3659/4885CCR5 2677/4885 |
| US-20110015252-A1 | LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE | PCSK9, PCSK7, PCSK6 | SIGMAR1 4641/4885ALDH1A1 4742/4885CCR5 2728/4885 |
| US-11827883-B2 | Dosages and methods for delivering lipid formulated nucleic acid molecules | POLM, POLRMT, ADAR | SIGMAR1 729/4885ALDH1A1 3723/4885CCR5 534/4885 |
| US-20120095075-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SIGMAR1 2708/4885ALDH1A1 3847/4885CCR5 457/4885 |
| US-20230203496-A1 | SIRNA COMPOSITIONS AND METHODS FOR SILENCING GPAM (GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1, MITOCHONDRIAL) EXPRESSION | POLRMT, ACAT1, GPAA1 | SIGMAR1 4635/4885ALDH1A1 2927/4885CCR5 4026/4885 |
| US-20120027796-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, ABCB4, LCAT | SIGMAR1 2216/4885ALDH1A1 4201/4885CCR5 798/4885 |
| US-20100267806-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES | KIF5A, KIF5C, KIF11 | SIGMAR1 4667/4885ALDH1A1 4160/4885CCR5 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.